Jonas Moecking

Publication Activity (10 Years)

Years Active: 2022-2023
Publications (10 Years): 5

Top Topics

Nlrp Inflammasome

Top Venues

Nature communications

The Journal of experimental medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Anja Kopp, Gregor Hagelueken, Isabell Jamitzky, Jonas Moecking, Lisa D J Schiffelers, Florian Ingo Schmidt, Matthias Geyer
Pyroptosis inhibiting nanobodies block Gasdermin D pore formation. Nature communications 14 (1) (2023)
Christophe Rouillon, Niels Schneberger, Haotian Chi, Katja Blumenstock, Stefano Da Vela, Katrin Ackermann, Jonas Moecking, Martin F Peter, Wolfgang Boenigk, Reinhard Seifert, Bela Ernest Bode, Jonathan L Schmid-Burgk, Dmitri I Svergun, Matthias Geyer, Malcolm F White, Gregor Hagelueken
Antiviral signaling by a cyclic nucleotide activated CRISPR protease. Nature (2022)
Lea-Marie Jenster, Karl-Elmar Lange, Sabine Normann, Anja Vom Hemdt, Jennifer Deborah Wuerth, Lisa D J Schiffelers, Yonas M Tesfamariam, Florian N Gohr, Laura Klein, Ines H Kaltheuner, Stefan Ebner, Dorothee Johanna Lapp, Jacob Mayer, Jonas Moecking, Hidde L Ploegh, Eicke Latz, Rüdiger Klein, Matthias Geyer, Beate Mareike Kümmerer, Florian Ingo Schmidt
P38 kinases mediate NLRP1 inflammasome activation after ribotoxic stress response and virus infection. The Journal of experimental medicine 220 (1) (2022)
Martin F Peter, Jan Andreas Ruland, Peer Depping, Niels Schneberger, Emmanuele Severi, Jonas Moecking, Karl Gatterdam, Sarah Tindall, Alexandre Durand, Veronika Heinz, Jan Peter Siebrasse, Paul-Albert Koenig, Matthias Geyer, Christine Ziegler, Ulrich Kubitscheck, Gavin Hugh Thomas, Gregor Hagelueken
Structural and mechanistic analysis of a tripartite ATP-independent periplasmic TRAP transporter. Nature communications 13 (1) (2022)
Inga V Hochheiser, Michael Pilsl, Gregor Hagelueken, Jonas Moecking, Michael Marleaux, Rebecca Brinkschulte, Eicke Latz, Christoph Engel, Matthias Geyer
Structure of the NLRP3 decamer bound to the cytokine release inhibitor CRID3. Nature 604 (7904) (2022)